Mirum Pharmaceuticals Compliance with Nasdaq Rule for Inducement Grants
Monday, 10 June 2024, 23:12
Mirum Pharmaceuticals Compliance with Nasdaq Rule
Mirum Pharmaceuticals has announced the issuance of inducement grants in compliance with Nasdaq Rule 5635(c)(4), signaling the company's dedication to integrity and regulatory adherence.
The strategic decision underlines Mirum's commitment to transparent business practices, fostering credibility and assurance among its stakeholders and the investment community.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.